MedTrace Logo

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

NCT01926002 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-07-16

No results posted yet for this study

Summary

The primary hypothesis of the study is single doses of MK-8351 will reduce the baseline early asthmatic response (EAR) as assessed by area under the curve from 0-3 hours (AUC0-3hr) of forced expiratory volume (FEV1) when compared to placebo.

Conditions

Interventions

DRUG

Low-Dose MK-8351

Single administration of low-dose MK-8351.

DRUG

High-Dose MK-8351

High-Dose MK-8351 administered as a single inhaled dose.

DRUG

Placebo to MK-8351

Single-Dose Matching placebo to high-dose or low-dose MK-8351.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-04-30
Completion
2014-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926002 on ClinicalTrials.gov